Newswise — Researchers at University College London have created the first massive open online course on four of the less-common forms of dementia. Developed by Timothy Shakespeare, with Sebastian Crutch and Nick Fox, “The Many Faces of Dementia” will kick off on March 14. Over the course of a month -— two hours per week for autosomal-dominant AD, frontotemporal dementia, dementia with Lewy bodies, and posterior cortical atrophy -— learners can watch videos, read articles, and take quizzes while discussing the content with fellow learners.
The aim is to share the information gathered about these poorly understood conditions with a global audience. Hosted by FutureLearn, a social learning platform owned by The Open University, the MOOC features documentary video interviews and research stories, and online articles and quizzes. For full story, see Gabrielle Strobel's story.
About UsFounded in 1996, Alzforum is a news and information resource website dedicated to helping researchers accelerate discovery and advance development of diagnostics and treatments for Alzheimer’s disease and related disorders.
Our site expands the traditional mode of scientific communication by reporting the latest scientific findings and industry news with insightful analysis that puts breaking news into context. We advance research by developing open-access databases of curated, highly specific scientific content to visualize and facilitate the exploration of complex data. Alzforum is a platform to disseminate the evolving knowledge around basic, translational, and clinical research in the field of AD.
Alzforum is supported by a team with backgrounds in science, journalism, information technology, design, and data science. Together with a distinguished Scientific Advisory Board, and the active participation of a global network of scientists, we strive to produce unbiased content to a rigorous editorial standard.
Alzforum is operated by the Biomedical Research Forum (BRF) LLC. BRF is a wholly owned subsidiary of FMR LLC. FMR LLC and its affiliates invest broadly in many companies, including life sciences and pharmaceutical companies. Alzforum does not endorse any specific product or scientific approach.
RSS